Posted by: DrugsNews on: 15 Mar, 2010
Novartis Reports Preliminary Results Of Navigator Trial
Novartis has reported that results from a study involving more than 9,000 people showed that the high blood pressure medicine Valsartan delayed progression to type 2 diabetes in patients with cardiovascular disease or risk factors and impaired glucose tolerance (IGT).
Read more about Novartis Reports Preliminary Results Of Navigator Trial
Posted by: DrugsNews on: 15 Mar, 2010
Medtronic Reports Clinical Results For Endeavor Drug-eluting Stent
Medtronic has presented five-year findings of Endeavor drug-eluting stent (DES) as a treatment for coronary artery disease at the American College of Cardiology’s 59th Scientific Session.
Read more about Medtronic Reports Clinical Results For Endeavor Drug-eluting Stent
Posted by: DrugsNews on: 15 Mar, 2010
West Coast Clinical Trials Inaugurates Second Facility In Costa Mesa, California
West Coast Clinical Trials, a private minority-owned independent Phase I-IV clinical research organisation located in Southern California, has opened a second facility in Costa Mesa, California.
Read more about West Coast Clinical Trials Inaugurates Second Facility In Costa Mesa, California
Posted by: DrugsNews on: 15 Mar, 2010
Quintiles Opens Clinical Research Facility In Kenya
Quintiles, a US-based biopharma services company offering clinical, commercial, consulting and capital solutions, has expanded its clinical research capacity in Africa by opening an office in Nairobi, Kenya.
Read more about Quintiles Opens Clinical Research Facility In Kenya
Posted by: DrugsNews on: 15 Mar, 2010
NHC Group Expands To India
NHC Group (NHC), an Australian audiology service provider, is set to launch operations in india through its subsidiary NHC Hearing Care (India).
Read more about NHC Group Expands To India
Posted by: DrugsNews on: 15 Mar, 2010
Sigma-Aldrich To Sell Pfizer Bioactive Small Molecule Compounds
Sigma-Aldrich has entered into an agreement with Pfizer to sell approximately 100 Pfizer-developed small molecule compounds to life science researchers for target characterisation, assay development, screening and in-vivo animal model applications.
Read more about Sigma-Aldrich To Sell Pfizer Bioactive Small Molecule Compounds
Posted by: DrugsNews on: 15 Mar, 2010
GSK Receives Marketing Authorisation For Revolade
GlaxoSmithKline (GSK) has received marketing authorisation from European Commission (EC) for its Revolade (eltrombopag), used in the oral treatment of thrombocytopenia (reduced platelet count) in adults with the blood disorder chronic immune (idiopathic) thrombocytopenic purpura (ITP).
Read more about GSK Receives Marketing Authorisation For Revolade
Posted by: DrugsNews on: 15 Mar, 2010
Manhattan Pharma Merges With Ariston Pharma
Manhattan Pharmaceuticals (Manhattan) has entered into a definitive agreement and plan of merger and completed the merger transaction with Ariston Pharmaceuticals. As a result of the merger, Ariston became a wholly-owned subsidiary of Manhattan.
Read more about Manhattan Pharma Merges With Ariston Pharma
Posted by: DrugsNews on: 15 Mar, 2010
Ipsen Initiates Two Phase II Clinical Studies Of BIM 23A760
Ipsen has initiated dosing in two Phase II clinical studies to evaluate efficacy and safety of BIM 23A760 in two groups of patients, one suffering from carcinoid syndrome due to neuroendocrine tumors, the other from acromegaly.
Read more about Ipsen Initiates Two Phase II Clinical Studies Of [...]
Posted by: DrugsNews on: 15 Mar, 2010
Vernalis Achieves Milestone Under Novartis Collaboration
Vernalis, a development stage pharma company with expertise both in de novo fragment and structure-based drug discovery and pre-clinical and clinical development, has achieved a milestone under collaboration with Novartis on the oncology target Hsp90.
Read more about Vernalis Achieves Milestone Under Novartis Collaboration
